Published 2 days ago • loading... • Updated 2 days ago

Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381

Rakuten Medical announced the global Phase 3 ASP-1929-381 trial is expanding enrollment to Taiwan with a Trial in Progress poster at ASCO 2025 in Chicago.
The trial focuses on patients in Taiwan and globally who experience a return or spread of squamous cell carcinoma in the head and neck region, a situation where mortality is high and nearly 50% of affected individuals survive less than one year.
ASP-1929 photoimmunotherapy combined with pembrolizumab is evaluated as a first-line treatment against standard pembrolizumab-based care in a randomized, open-label Phase 3 study involving over 10 clinical sites in the US and Taiwan.
The global Phase 3 study will enroll 412 patients to evaluate overall survival and complete response rates, with patient recruitment in Japan expected to commence soon. Anastasios Maniakas expressed enthusiasm about presenting the ongoing trial’s findings at ASCO 2025.
This trial may advance therapeutic options that could prolong survival for patients with recurrent HNSCC, reflecting Rakuten Medical’s mission to develop innovative photoimmunotherapy treatments worldwide.

Insights by Ground AI

Does this summary seem wrong?

42 Articles

All

Left

Center

Right

ABC FOX Montana

+41 Reposted by 41 other sources

Center

Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan expected to follow as part of global study start-up

2 days ago·Missoula, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year